Cargando…

Sustainable Control of Onchocerciasis: Ocular Pathology in Onchocerciasis Patients Treated Annually with Ivermectin for 23 Years: A Cohort Study

The evolution and persistence of ocular pathology was assessed in a cohort of Onchocerca volvulus infected patients treated annually with ivermectin for 23 years. Patients were resident in rural Central and Kara Region of Togo and ocular examinations included testing of visual acuity, slit lamp exam...

Descripción completa

Detalles Bibliográficos
Autores principales: Banla, Méba, Tchalim, Solim, Karabou, Potochoziou K., Gantin, Richard G., Agba, Aide I., Kére-Banla, Abiba, Helling-Giese, Gertrud, Heuschkel, Christoph, Schulz-Key, Hartwig, Soboslay, Peter T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4041847/
https://www.ncbi.nlm.nih.gov/pubmed/24887413
http://dx.doi.org/10.1371/journal.pone.0098411
_version_ 1782318723468623872
author Banla, Méba
Tchalim, Solim
Karabou, Potochoziou K.
Gantin, Richard G.
Agba, Aide I.
Kére-Banla, Abiba
Helling-Giese, Gertrud
Heuschkel, Christoph
Schulz-Key, Hartwig
Soboslay, Peter T.
author_facet Banla, Méba
Tchalim, Solim
Karabou, Potochoziou K.
Gantin, Richard G.
Agba, Aide I.
Kére-Banla, Abiba
Helling-Giese, Gertrud
Heuschkel, Christoph
Schulz-Key, Hartwig
Soboslay, Peter T.
author_sort Banla, Méba
collection PubMed
description The evolution and persistence of ocular pathology was assessed in a cohort of Onchocerca volvulus infected patients treated annually with ivermectin for 23 years. Patients were resident in rural Central and Kara Region of Togo and ocular examinations included testing of visual acuity, slit lamp examination of the anterior eye segment and the eye fundus by ophthalmoscopy. Before ivermectin treatment, vivid O.volvulus microfilariae (MF) were observed in the right and left anterior eye chamber in 52% and 42% of patients (n = 82), and dead MF were seen in the right and left cornea in 24% and 15% of cases, respectively. At 23 years post initial treatment (PIT), none of the patients (n = 82) presented with MF in the anterior chamber and cornea. A complete resolution of punctate keratitis (PK) lesions without observable corneal scars was present at 23 years PIT (p<0.0001), and sclerosing keratitits (SK) lessened by half, but mainly in patients with lesions at early stage of evolution. Early-stage iridocyclitis diminished from 42%(rE) and 40%(lE) to 13% (rE+lE)(p<0.0001), but advanced iridocyclitis augmented (p<0.001) at 23 years PIT compared to before ivermectin. Advanced-stage papillitis and chorioretinitis did not regress, while early-stage papillitis present in 28%(rE) and 27%(lE) of patients at before ivermectin regressed to 17%(rE) and 18%(lE), and early-stage chorioretinitis present in 51%(rE+lE) of cases at before ivermectin was observed in 12%(rE) and 13%(lE) at 23 years PIT (p<0.0001). Thus, regular annual ivermectin treatment eliminated and prevented the migration of O. volvulus microfilariae into the anterior eye chamber and cornea; keratitis punctata lesions resolved completely and early-stage sclerosing keratitits and iridocyclitis regressed, whilst advanced lesions of the anterior and posterior eye segment remained progressive. In conclusion, annual ivermectin treatments may prevent the emergence of ocular pathology in those populations still exposed to O.volvulus infection. Trial Registration: www.pactr.org PACTR201303000464219)
format Online
Article
Text
id pubmed-4041847
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-40418472014-06-09 Sustainable Control of Onchocerciasis: Ocular Pathology in Onchocerciasis Patients Treated Annually with Ivermectin for 23 Years: A Cohort Study Banla, Méba Tchalim, Solim Karabou, Potochoziou K. Gantin, Richard G. Agba, Aide I. Kére-Banla, Abiba Helling-Giese, Gertrud Heuschkel, Christoph Schulz-Key, Hartwig Soboslay, Peter T. PLoS One Research Article The evolution and persistence of ocular pathology was assessed in a cohort of Onchocerca volvulus infected patients treated annually with ivermectin for 23 years. Patients were resident in rural Central and Kara Region of Togo and ocular examinations included testing of visual acuity, slit lamp examination of the anterior eye segment and the eye fundus by ophthalmoscopy. Before ivermectin treatment, vivid O.volvulus microfilariae (MF) were observed in the right and left anterior eye chamber in 52% and 42% of patients (n = 82), and dead MF were seen in the right and left cornea in 24% and 15% of cases, respectively. At 23 years post initial treatment (PIT), none of the patients (n = 82) presented with MF in the anterior chamber and cornea. A complete resolution of punctate keratitis (PK) lesions without observable corneal scars was present at 23 years PIT (p<0.0001), and sclerosing keratitits (SK) lessened by half, but mainly in patients with lesions at early stage of evolution. Early-stage iridocyclitis diminished from 42%(rE) and 40%(lE) to 13% (rE+lE)(p<0.0001), but advanced iridocyclitis augmented (p<0.001) at 23 years PIT compared to before ivermectin. Advanced-stage papillitis and chorioretinitis did not regress, while early-stage papillitis present in 28%(rE) and 27%(lE) of patients at before ivermectin regressed to 17%(rE) and 18%(lE), and early-stage chorioretinitis present in 51%(rE+lE) of cases at before ivermectin was observed in 12%(rE) and 13%(lE) at 23 years PIT (p<0.0001). Thus, regular annual ivermectin treatment eliminated and prevented the migration of O. volvulus microfilariae into the anterior eye chamber and cornea; keratitis punctata lesions resolved completely and early-stage sclerosing keratitits and iridocyclitis regressed, whilst advanced lesions of the anterior and posterior eye segment remained progressive. In conclusion, annual ivermectin treatments may prevent the emergence of ocular pathology in those populations still exposed to O.volvulus infection. Trial Registration: www.pactr.org PACTR201303000464219) Public Library of Science 2014-06-02 /pmc/articles/PMC4041847/ /pubmed/24887413 http://dx.doi.org/10.1371/journal.pone.0098411 Text en © 2014 Banla et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Banla, Méba
Tchalim, Solim
Karabou, Potochoziou K.
Gantin, Richard G.
Agba, Aide I.
Kére-Banla, Abiba
Helling-Giese, Gertrud
Heuschkel, Christoph
Schulz-Key, Hartwig
Soboslay, Peter T.
Sustainable Control of Onchocerciasis: Ocular Pathology in Onchocerciasis Patients Treated Annually with Ivermectin for 23 Years: A Cohort Study
title Sustainable Control of Onchocerciasis: Ocular Pathology in Onchocerciasis Patients Treated Annually with Ivermectin for 23 Years: A Cohort Study
title_full Sustainable Control of Onchocerciasis: Ocular Pathology in Onchocerciasis Patients Treated Annually with Ivermectin for 23 Years: A Cohort Study
title_fullStr Sustainable Control of Onchocerciasis: Ocular Pathology in Onchocerciasis Patients Treated Annually with Ivermectin for 23 Years: A Cohort Study
title_full_unstemmed Sustainable Control of Onchocerciasis: Ocular Pathology in Onchocerciasis Patients Treated Annually with Ivermectin for 23 Years: A Cohort Study
title_short Sustainable Control of Onchocerciasis: Ocular Pathology in Onchocerciasis Patients Treated Annually with Ivermectin for 23 Years: A Cohort Study
title_sort sustainable control of onchocerciasis: ocular pathology in onchocerciasis patients treated annually with ivermectin for 23 years: a cohort study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4041847/
https://www.ncbi.nlm.nih.gov/pubmed/24887413
http://dx.doi.org/10.1371/journal.pone.0098411
work_keys_str_mv AT banlameba sustainablecontrolofonchocerciasisocularpathologyinonchocerciasispatientstreatedannuallywithivermectinfor23yearsacohortstudy
AT tchalimsolim sustainablecontrolofonchocerciasisocularpathologyinonchocerciasispatientstreatedannuallywithivermectinfor23yearsacohortstudy
AT karaboupotochoziouk sustainablecontrolofonchocerciasisocularpathologyinonchocerciasispatientstreatedannuallywithivermectinfor23yearsacohortstudy
AT gantinrichardg sustainablecontrolofonchocerciasisocularpathologyinonchocerciasispatientstreatedannuallywithivermectinfor23yearsacohortstudy
AT agbaaidei sustainablecontrolofonchocerciasisocularpathologyinonchocerciasispatientstreatedannuallywithivermectinfor23yearsacohortstudy
AT kerebanlaabiba sustainablecontrolofonchocerciasisocularpathologyinonchocerciasispatientstreatedannuallywithivermectinfor23yearsacohortstudy
AT hellinggiesegertrud sustainablecontrolofonchocerciasisocularpathologyinonchocerciasispatientstreatedannuallywithivermectinfor23yearsacohortstudy
AT heuschkelchristoph sustainablecontrolofonchocerciasisocularpathologyinonchocerciasispatientstreatedannuallywithivermectinfor23yearsacohortstudy
AT schulzkeyhartwig sustainablecontrolofonchocerciasisocularpathologyinonchocerciasispatientstreatedannuallywithivermectinfor23yearsacohortstudy
AT soboslaypetert sustainablecontrolofonchocerciasisocularpathologyinonchocerciasispatientstreatedannuallywithivermectinfor23yearsacohortstudy